When: Price $101 on 50 SMA reclaim with volume

Then: Re-enter 20% of trimmed position (thesis repair signal)

40-50% position trim with stops tightening to $87-88 and re-entry only above 50 SMA at $101.11

• Forward EPS of $8.51 is 32% above all-time high of $6.47, a heroic assumption
• Sequential growth anemic at 1.4% from Q1 to Q2 2026 despite easy year-over-year comps
• Structural PBM overhangs: Mark Cuban, FTC scrutiny, ACA exchange contraction, UNH utilization warning
• 2.86% dividend yield is not a floor—share repurchases suspended in 2025 while dividends grew
• Beta of 0.60 is backward-looking; idiosyncratic risk is high with extreme net income volatility
• Net income: $8.34 billion (2023), $4.61 billion (2024), $1.77 billion (2025), with $5.24 billion impairment in 2025
• Operating margins of 3.86% leave minimal buffer for cost shocks or regulatory surprises
• Negative tangible book value means equity is essentially goodwill from Aetna acquisition
• MACD histogram making higher lows for 12 straight sessions; ATR compressed in coiling pattern
• 200 SMA rising at $85; price 9.2% above; long-term uptrend technically intact
• Q2 2026 results flattering due to weak Q2 2025 comp: revenue +7.2%, net income +193%, FCF +338%
• Conservative floor trim: 40%; willingness to go to 50% if confirmed close below 10 EMA with expanding volume
• Stop at $83.50 but ratchet to $87-88 as position shrinks on smaller exposure
• Re-entry trigger: daily close above 50 SMA at $101.11 with volume confirmation, not just 10 EMA reclaim

→ vs aggressive: Being too confident about downside certainty; MACD divergence failure to $88.30 is treated as high-probability when 200 SMA is rising, ATR is compressed (coiling pattern resolves both ways), and MACD histogram shows 12 straight higher lows suggesting rebound to $100 is plausible

→ vs neutral: 2.86% dividend yield is not a floor—management already suspended buybacks in 2025 to preserve balance sheet; dividend itself becomes the lever they pull if FCF deteriorates

→ vs neutral: Beta of 0.60 does not make CVS defensive; beta is backward-looking price correlation; idiosyncratic risk is high given net income volatility and thin 3.86% operating margins

→ vs neutral: Q2 2026 recovery narrative is flawed—easy year-over-year comps due to weak Q2 2025 and impairment-distorted 2024; sequential growth of 1.4% shows flat trajectory, not acceleration

→ vs neutral: Negative tangible book value means equity is essentially goodwill; goodwill is the first thing written down when the thesis breaks

Trim 30-35% with scaled execution and tiered re-entry; maintain residual position with hard stop at $83.50

• Proposed trim of 30-35% executed in three tranches: roughly a third at $92.50, a third at $93.00 to $93.20, and a third at $93.50 for blended exit around $93
• Hard stop at $83.50 gives residual position approximately 10 dollars or 4x ATR of room below 200 SMA at $85.06
• Three-tranche re-entry: Tranche one (40% of trimmed cash) reloads at $88 to $88.50 on Bollinger lower band hold with 200 SMA intact; Tranche two (40%) reloads at $94 to $95 on 10 EMA reclaim with positive MACD crossover and histogram above zero; Tranche three (20%) reloads at $101 on 50 SMA reclaim with volume expansion
• Challenges aggressive analyst's 40% trim as too high given 12 consecutive sessions of higher lows in MACD histogram and real FCF generation of $5.65 billion up 338% YoY
• Challenges conservative analyst's 50% trim and tight $87-$88 stop as too aggressive, arguing 2.86% yield and 2.9x ATR stop width will trigger on routine volatility before thesis plays out
• Positions CVS as suitable for higher-for-longer macro given 10.9x forward earnings, 0.60 beta, and 2.86% yield
• Q2 2026 debt declined from $82.7 billion to $76.3 billion representing $6.4 billion deleveraging over approximately six quarters
• Operating income of $4.70 billion in Q2 represents second consecutive quarter above $4.6 billion

→ vs aggressive: 12 consecutive sessions of higher lows in MACD histogram indicates momentum shift not noise; divergences that fail usually fail within 5-6 sessions, not 12; 200 SMA at $85.06 rising with price 9.2% above it is structural floor

→ vs aggressive: Q2 FCF of $5.65 billion up 338% YoY is real cash generation, not soft comp artifact; 1.4% sequential net income growth paired with $4.70 billion operating income shows constructive trajectory

→ vs aggressive: 40% trim with undefined re-entry trigger is incomplete, not aggressive; must define exact reload levels and conditions

→ vs conservative: 50% trim is too aggressive given 2.86% yield and demonstrated dividend commitment despite deleveraging priority

→ vs conservative: $87-$88 stop at 5-6 dollars below current equals only 2-2.5x ATR, which is noise floor; will get stopped out on routine oversold bounce before thesis plays out

→ vs conservative: Single re-entry trigger at $101 (8.8% rally from $92.92 entry) misses 90% of any bounce; $88 to $96 on way to $101 would occur without position